List Price: unavailable
Sale Price: Too low to display.
No description available.
No features available.
- 'No new videos.'
Curl error no: 56 DescriptionRecv failure: Connection reset by peer
The number of people developing the deadliest form of skin cancer continues to rise, but people are still not doing enough to protect themselves. That is the opinion of the British Association of Dermatologists, which says behaviour concerning exposure to the sun’s rays is failing to improve, despite understanding of the disease increasing.
The Script Concordance test (SCT) is a reliable and valid tool to evaluate clinical reasoning in complex situations where experts’ opinions may be divided. Scores reflect the degree of concordance between the performance of examinees and that of a reference panel of experienced physicians. The purpose of this study is to demonstrate SCT’s usefulness in radiation oncology.
A 90 items radiation oncology SCT was administered to 155 participants. Three levels of experience were tested: medical students (n = 70), radiation oncology residents (n = 38) and radiation oncologists (n = 47). Statistical tests were performed to assess reliability and to document validity.
After item optimization, the test comprised 30 cases and 70 questions. Cronbach alpha was 0.90. Mean scores were 51.62 (plus or minus 8.19) for students, 71.20 (plus or minus 9.45) for residents and 76.67 (plus or minus 6.14) for radiation oncologists. The difference between the three groups was statistically significant when compared by the Kruskall-Wallis test (p < 0.001).
The SCT is reliable and useful to discriminate among participants according to their level of experience in radiation oncology. It appears as a useful tool to document the progression of reasoning during residency training.
ORLANDO, Fla. — Pfizer announced today results from studies evaluating the company’s investigational anti-insulin growth factor- type 1 receptor (IGF-1R) antibody, figitumumab (CP-751,871), in patients with non-small cell lung cancer (NSCLC). A total of three abstracts were presented at the 45th Annual American Society of Clinical Oncology (ASCO) annual meeting in Orlando. “As we try to find the right drug to use in the right setting for each patient, we are encouraged by these data, suggesting a relationship between tumor histology and response to figitumumab,” said Dr. Mace Rothenberg, senior vice president of clinical development and medical affairs for Pfizer’s Oncology Business Unit. “Given that patients with adva…